Elizabeth R. Volkmann
European Respiratory Journal 2023 61: 2300614; DOI: 10.1183/13993003.00614-2023
Extract
Interstitial lung diseases (ILDs) encompass a heterogeneous group of diseases, including autoimmune ILD, hypersensitivity pneumonitis, occupational diseases, granulomatous diseases and idiopathic pneumonitis [1]. Despite their diverse aetiologies, ILDs share common clinical features and are a major contributor to disability and premature death [2]. In recent years, approved and emerging therapies for ILD have increased treatment options for patients [3]. This expanding therapeutic pipeline has created an opportunity to study how combining therapies may improve outcomes for patients with ILD.
Footnotes
-
Conflict of interest: E.R. Volkmann is supported by the National Heart, Lung, and Blood Institute (grant number K23 HL150237) and reports the following financial relationships outside of the submitted work on autoimmune-associated ILD: consulting for Boehringer Ingelheim, Roche, CSL Behring and GSK, speaking for Boehringer Ingelheim, and institutional support received for performing studies in systemic sclerosis for Kadmon, Forbius, Boehringer Ingelheim, Horizon and Prometheus.
- Received April 11, 2023.
- Accepted April 13, 2023.
- Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org
